ストックスクリーナーアプリを入手
1.42
2.07%
-0.03
アフターアワーズ：
1.44
0.02
+1.41%
Medicinova Inc (MNOV) 最新ニュース
MediciNova reports mixed MN-001 results. Analysts give MediciNova stock a Moderate Buy rating - ad-hoc-news.de
MediciNova, Inc. (MNOV) Stock Price, News, Quote & History - Yahoo! Finance Canada
MediciNova’s MN-001 trial misses primary endpoints in NAFLD By Investing.com - Investing.com Nigeria
MediciNova’s MN-001 trial misses primary endpoints in NAFLD By Investing.com - Investing.com South Africa
MediciNova CEO Provides Shareholder Update - GlobeNewswire Inc.
MediciNova CEO Provides Shareholder Update - GlobeNewswire
Two cholesterol measures improved significantly, but the trial missed its primary endpoints. - Stock Titan
Issuance/retirement of debt (net) of MediciNova, Inc. – TSE:4875 - TradingView
MediciNova Company Profile & Introduction - Moomoo
MediciNova to Participate in the Maxim Growth Summit - Yahoo Finance Australia
MediciNova to Participate in the Maxim Growth Summit - GlobeNewswire Inc.
MediciNova to Participate in the Maxim Growth Summit - Yahoo Finance
MediciNova to Participate in the Maxim Growth Summit - GlobeNewswire
MediciNova (4875) Stock Forum and Discussion - Moomoo
MediciNova stock gained 9.20 percent after mixed Phase 2 data - AD HOC NEWS
MediciNova Company Profile & Introduction - Moomoo
Maxim Group Maintains MediciNova(MNOV.US) With Buy Rating, Maintains Target Price $6 - Moomoo
3D Investment Partners Updates MediciNova Holdings, Reports Private Sale and Swap Agreements - Kalkine Media
Two holders sold 640,000 MediciNova (NASDAQ: MNOV) shares and still report an ownership stake. - Stock Titan
After a sale, an investment manager still reports 4.86 million MediciNova (MNOV) shares held indirectly. - Stock Titan
H.C. Wainwright reiterates Buy on MediciNova stock, $10 target - Investing.com
MediciNova (NasdaqGM:MNOV) Stock Forecast & Analyst Predictions - Simply Wall Street
Form 8K MediciNova Inc For: 28 September By Investing.com - Investing.com Nigeria
MediciNova extends office lease to 2030 and agrees to rent increases By Investing.com - Investing.com Nigeria
MediciNova extends office lease to 2030 and agrees to rent increases - Investing.com
MediciNova extends office lease to 2030 and agrees to rent increases By Investing.com - Investing.com Australia
Form 8K MediciNova Inc For: 28 September By Investing.com - Investing.com South Africa
Form 8K MediciNova Inc For: 28 September By Investing.com - Investing.com India
Form 8K MediciNova Inc For: 28 September By Investing.com - Investing.com Canada
Form 8K MediciNova Inc For: 28 September By Investing.com - Investing.com UK
Rent increases take effect in February 2027 under MediciNova's (MNOV) amended lease. - Stock Titan
Why Is MediciNova Stock Tumbling Today?MediciNova (NASDAQ:MNOV) - Benzinga
MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints - Yahoo Finance
Why is MediciNova stock sliding today? By Investing.com - Investing.com South Africa
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data - Yahoo Finance
Why is MediciNova stock sliding today? - Investing.com
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data - Investing.com
MediciNova reports mixed phase 2 results for MN-001 drug trial - Investing.com Nigeria
MediciNova misses both Phase 2 endpoints despite HDL gains - Mugglehead Investment Magazine
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) - GlobeNewswire Inc.
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) - GlobeNewswire
A 40-person study found more “good” cholesterol with MediciNova's drug, but no significant liver-fat difference. - Stock Titan
MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles - Yahoo Finance
MediciNova completes double-blind phase of ALS drug trial By Investing.com - Investing.com Canada
MediciNova completes double-blind phase of ALS drug trial - Investing.com
MediciNova completes double-blind phase of ALS drug trial By Investing.com - Investing.com Nigeria
MediciNova Announces Last Patient, Last Visit in Double-Blind Portion of COMBAT-ALS Phase 2b/3 Trial of MN-166 for ALS - Quiver Quantitative
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast) - Yahoo Finance Singapore
The blinded phase of an ALS drug trial is complete. Results are expected by year-end. - Stock Titan
MediciNova Announces Completion of Last Patient, Last Visit - GlobeNewswire
4.22%
大文字化:
|
ボリューム (24 時間):